Celcuity Inc. (CELC)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 10.76 |
Market Cap | 417.71M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.67 |
PE Ratio (ttm) | -4.21 |
Forward PE | n/a |
Analyst | Buy |
Ask | 11.76 |
Volume | 135,162 |
Avg. Volume (20D) | 286,871 |
Open | 11.21 |
Previous Close | 11.21 |
Day's Range | 11.00 - 11.91 |
52-Week Range | 10.35 - 22.19 |
Beta | undefined |
About CELC
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I...
Analyst Forecast
According to 6 analyst ratings, the average rating for CELC stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 140.00% from the latest price.